Cell Therapeutics Reaches Agreement with FDA on SPA for Planned Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis
October 07, 2013 at 05:56 AM EDT
Cell Therapeutics (NASDAQ: CTIC ) today announced that the company reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the planned pivotal Phase 3 clinical trial, known as the PERSIST-2 trial, evaluating pacritinib compared to best available therapy, including approved JAK2
